Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Saccharomyces boulardii in very low birth weight infants to prevent necrotizing enterocolitis
IRCT2012071410279N1Phase 3Completed
- Sponsor
- General Directorate of Pharmacy (Iraq)
- Start
- Oct 2010
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of saccharomyces boulardii in necrotizing enterocolitis (NEC) and neonatal sepsis, sponsored by General Directorate of Pharmacy (Iraq). Started Oct 2010; status: completed.
02
Drugs
saccharomyces boulardii
03
Conditions
necrotizing enterocolitis (NEC)neonatal sepsis
Beyond the preview
Go deeper on IRCT2012071410279N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2012071410279N1.